Paradoxes of cellular immune responses evoked by mRNA injections - fostered by cross-priming and cross-tolerance but at a high price

Preprint published

It has been a while. I have been working day and night to better understand mRNA “vaccine” immunity. The more I have looked into it, the more I have seen inconsistencies and gaps. Just lots of open questions and concerns!

I was even more surprised when I studied a 2024 publication in Nature Communications. One of their results, represented as a figure, clearly showed some unexpected antigen processing and presentation pathways. In the text portion of this article, it came across as if it was the canonical pathway they found. Yet, the details provided in the figure were unequivocal. Did the authors merely cling to the prevailing narrative and not notice? I don’t know.

This has kept me busy for quite some time. I am now happy that the first part of my work has been published as a preprint. A follow-up should be ready soon. I also have a long write-up of how and why I ended up thinking along these lines, and why I argue these findings may be rather important. But I don’t know if I will send it all to a preprint server (deep down, I think I may end up writing another book – I already have quite some material).

Preprint: https://osf.io/preprints/osf/fjnav_v1

Admittedly, some of these writings are rather long. I tried to clearly lay out how I was dancing around some issues I regard as critical. The way it is written is so it first makes sense to me. Much of what I have come up with radically undermines key beliefs about mRNA technologies. If this proves correct, it will have far-reaching consequences.

Here is the abstract:

A complete understanding of the immunological mechanisms of the mRNA vaccines has remained elusive. This article focuses on key questions that demonstrate the limits of our comprehension of Cytotoxic T Lymphocytes (CTL) activation and details paradoxical observations related to the immune response evoked. In August 2024, a study published in Nature Communications provided vital insights into innate immune processes triggered by the mRNA COVID-19 injections, and how they are linked to spike-specific cellular immune responses. Some of their findings have remained overlooked. While they offer a general framework of early immune activation, their enrichment of mRNA vaccine transcripts in injection-site fibroblasts indicates a pivotal role of Class I MHC processing and presentation of exogenous antigens. For mRNA vaccines, the potential of cross-presentation is largely under-appreciated. Their mechanism of CTL activation widely presumes the canonical MHC-I pathway, following generation of the endogenous vaccine antigen and their processing and presentation by professional antigen-presenting cells (APC), and facilitated by appropriate co-stimulation, despite the stymied 1-methylpseudouridine modification to reduce innate responses. Here, several arguments are provided that make mRNA vaccines particularly prone to the alternative pathway, whereby certain APCs, via uptake of vaccine or self-antigens, or those of other infections, can effectively evoke CTL response induction. These mechanisms underlying cross-presentation of exogenous antigens disprove the notion that the T cell response is specific to the vaccine antigen alone, in line with the published effects seen of the mRNA COVID-19 injections to heterologous infections where they appear to either enhance or dampen immune responses. Reasons are provided why injection-induced cross-tolerance may play a substantial role in inducing peripheral tolerance both to SARS-CoV-2 and heterologous infections. In all, cross-priming or cross-tolerance evoked by the mRNA injections may offer explanations to some of the main open questions related to this platform but also raise substantial concerns of clinical and environmental ramifications.

The preprint is long. It first describes “paradoxical” findings of the mRNA “vaccine” responses, with a special orientation towards the unaccounted pathway. Ironically, for DNA “vaccines,” this possibility is well-established. But for the mRNA injections, it seems to have disappeared. The second part of the preprint describes some consequences. In short, this potential effectively disproves these products acting as vaccines, in several ways. For those who do not have the time to read the entire manuscript (fair enough), please see the 2 figures and a final table where I tried to summarize it all.

It would be important to get it published as a journal article. If anyone has any suggestions of where I could send it (or parts of it), please do let me know.

Again, this is theoretical work only. A follow-up manuscript will demonstrate my hypothesis is in line with some experimental findings made by some other group, very recently published in Nature Communications as well. While I tried to explain some issues, I am the first to admit that, in reality, the underlying pathways and processes are likely even more complex. I hope that what I described will at least lay some basis – and provide another strong reason that challenges the safety and applicability of these platforms.

Thanks for reading.